Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Similares en SciELO
Compartir
Salus
versión impresa ISSN 1316-7138
Resumen
LO PRESTI, Ana et al. Potential drug interactions in patients with cardiovascular disease and polypharmacy. Salus [online]. 2015, vol.19, n.2, pp.11-17. ISSN 1316-7138.
Cardiovascular disease is the leading cause of morbidity in the adult Venezuelan population, leading to a significant number of hospitalized patients receiving combination therapy, which may cause drug interactions (IF). The aim of this study was to evaluate potential IF polypharmacy in patients with cardiovascular disease. This was an observational, descriptive cross-sectional study; medical records of 87 hospitalized patients were reviewed with a stage of three days or more. The data collection form recorded: history number, age, gender, admission and discharge dates, type of cardiovascular disease; administered drugs, treatment start and completion dates. Identification of potential IF was performed using the TOX MED program. Results showed an average age of 63.82; predominantly males and potential association between IF nd prescription of more than seven drugs (p = 0.002). The most frequent diseases were acute coronary syndrome and hypertension; antithrombotic agents were the most commonly prescribed drugs. 519 IF potential were identified; pharmacokinetic 51 (30.32%) and pharmacodynamic 347 (69.68%), the most frequent ones being metabolism (84.79%) and synergism (75.79%), respectively. The highest percentage of potential pharmacokinetic IF was associated with atorvastatin - clopidogrel (22.52%), and pharmacodynamic with aspirin - heparin (15.71%). It is concluded that the number of pharmacokinetic or pharmacodynamic IF potential increases with the number of drugs that patients take..Key words: Potential drug interactions, drug-drug, cardiovascular patients, polypharmacy.
Palabras clave : Potential drug interactions; drug-drug; cardiovascular patients; polypharmacy.